BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company released its 1Q2024 results that showed margins improved to 95%, while 1Q revenue was 71 times higher than the year ago period, blowing past our estimates and posting its first profit.
